---
title: "PULM.US (PULM.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PULM.US/news.md"
symbol: "PULM.US"
name: "PULM.US"
parent: "https://longbridge.com/en/quote/PULM.US.md"
datetime: "2026-03-11T07:46:28.759Z"
locales:
  - [en](https://longbridge.com/en/quote/PULM.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PULM.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PULM.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/PULM.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/PULM.US/news.md)


# PULM.US (PULM.US) — Related News

### [](https://longbridge.com/en/news/277513058.md)
*2026-03-02T19:48:45.000Z*
> Pulmatrix shares are trading lower after a planned acquisition was rejected.

### [Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead](https://longbridge.com/en/news/277511348.md)
*2026-03-02T19:35:16.000Z*
> Pulmatrix shares fell after the privately-held pharma company opted to merge with Gyre Therapeutics instead. Gyre announ

### [Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities](https://longbridge.com/en/news/277470378.md)
*2026-03-02T13:00:00.000Z*
> Pulmatrix (PULM) announced the termination of its merger agreement with Cullgen, which was due to delays in regulatory a

### [Pulmatrix | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/277048212.md)
*2026-02-26T13:22:56.000Z*
### [Pulmatrix | 8-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/277046528.md)
*2026-02-26T13:08:54.000Z*
### [Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results | PULM Stock News](https://longbridge.com/en/news/277046441.md)
*2026-02-26T05:05:00.000Z*
> Pulmatrix, Inc. (Nasdaq: PULM) announced its year-end and fourth quarter financial results for 2025, focusing on a propo

### [Invasive fungal infections market in US to grow at 11.4% CAGR by 2034 due to new agents like Ibrexafungerp, Fosmanogepix, and Opelconazole.](https://longbridge.com/en/news/275373310.md)
*2026-02-09T22:33:50.000Z*
> The market for invasive fungal infections is projected to experience growth by 2034 due to the introduction of new treat

### [Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives | PULM Stock News](https://longbridge.com/en/news/270163611.md)
*2025-12-18T05:05:00.000Z*
> Pulmatrix and Cullgen are pursuing a merger, seeking approval from the China Securities Regulatory Commission. They have

### [Pulmatrix and Cullgen are pursuing a merger, supporting each other while exploring alternatives, seeking approval from China Securities Regulatory Commission.](https://longbridge.com/en/news/270166459.md)
*2025-12-18T13:08:51.000Z*
> Pulmatrix, headquartered in FRAMINGHAM, Mass., is showing ongoing support for Cullgen in their efforts to gain approval